Skip to main content

Table 2 Suggested preference of pharmacotherapy in type 2 diabetes based on cardiovascular effects

From: Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Acceptable Avoid No data
Established or at risk of heart failure
Metformin TZDs Meglitinides
Sulfonylureas DPP-4 inhibitorsa AGIs
SGLT-2 inhibitors   
Established cardiovascular disease
Metformin 1st generation sulfonylureas Meglitinides
2nd and 3rd generation sulfonylureas Rosiglitazone AGIs
Pioglitazone   
DPP-4 inhibitors   
SGLT-2 inhibitors   
  1. TZDs thiazolidinediones, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, SGLT-2 sodium glucose cotransporter 2, AGIs alpha-glucosidase inhibitors
  2. aSpecifically saxagliptin and alogliptin; note that sitagliptin may be used